Introduction
Voriconazole (UK-109,496) is a new monotriazole antifungal agent. It exhibits dose-dependent pharmacokinetics and is well-tolerated after oral or parenteral administration. 1 It has been reported to be effective in the treatment of acute or chronic invasive aspergillosis, and HIV-associated oral candidosis. [2] [3] [4] Previous in-vitro studies have shown it to have a broad spectrum of fungistatic action, including Aspergillus spp., Blastomyces dermatitidis, Candida spp., Coccidioides immitis, Cryptococcus neoformans, Histoplasma capsulatum, Penicillium marneffei, Scedosporium apiospermum and Sporothrix schenckii. [5] [6] [7] [8] [9] [10] [11] Voriconazole has been reported to have both fungistatic and fungicidal activities against a number of Aspergillus spp. 12, 13 However, the number of isolates that have been studied is limited, and there is a lack of comparative data for other filamentous fungi and antifungal agents. In this study, we compared the in-vitro fungistatic and fungicidal activities of voriconazole against 11 species of moulds with those of amphotericin B and the broad-spectrum triazole agent, itraconazole. The in-vitro testing method we employed was a microdilution adaptation of the standard broth macrodilution reference method of the National Committee for Clinical Laboratory Standards (NCCLS). Isolates were retrieved from storage in liquid nitrogen or water, subcultured on plates of Oxoid Sabouraud dextrose agar (Unipath Ltd, Basingstoke, UK) supplemented with 0.5% (w/v) chloramphenicol, and incubated at 30°C until adequate growth was obtained. To induce spore formation, the isolates were subcultured on slopes of Oxoid potato dextrose agar and incubated at 35°C for 7 days. Isolates of F. solani were incubated at 35°C for 2-3 days and then at 28-30°C for 4-5 days.
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Materials and methods
Isolates
Antifungal agents
Voriconazole was obtained from Pfizer Central Research, Sandwich, UK, and itraconazole was obtained from Janssen Research Foundation, Beerse, Belgium. Amphotericin B was obtained from Sigma Chemical Co., St Louis, MO, USA. Voriconazole and amphotericin B were dissolved in dimethyl sulphoxide. A stock solution of itraconazole was prepared in polyethylene glycol-400 with the aid of heating to 70°C. Further dilutions were made with RPMI-1640 medium (with L-glutamine, without bicarbonate) (Sigma), supplemented with glucose (2%) and buffered to pH 7.0 with 0.165 M morpholinopropanesulphonic acid (Sigma). The recommendations stated in the NCCLS document M27-A 14 were followed for the dilution of each antifungal agent. The antifungal agents were tested over a final concentration range of 0.03-16 mg/L.
Antifungal susceptibility tests
Broth microdilution MICs were determined in 96-well round-bottomed microtitre plates. Spore suspensions were prepared in RPMI-1640 medium and adjusted to a final inoculum of 0.4-5 10 4 spores/mL. The plates were incubated at 35°C and read after 24 h (A. corymbifera and R. arrhizus) or 48 h. The plates were shaken before the growth in each well was compared with that of the controls. The MIC for amphotericin B was defined as the lowest concentration at which there was 100% inhibition of growth, and for voriconazole and itraconazole as the lowest concentration at which there was 80% inhibition of growth compared with a drug-free control.
Determination of minimum lethal concentration
The minimum lethal concentration (MLC) was determined after 24 h (A. corymbifera and R. arrhizus) or 48 h incubation by removing 10 L of the contents from all wells showing no visible growth and spreading them on to Sabouraud dextrose agar plates. The plates were incubated at 35°C for 48 h. The MLC was defined as the lowest concentration at which 95% of the inoculum was killed.
Results
The 
Discussion
Azole antifungal agents interfere with fungal ergosterol biosynthesis through inhibition of a cytochrome P450-dependent enzyme, 14 -demethylase. The consequent depletion of ergosterol and accumulation of 14 -methylsterols, such as lanosterol, eburicol and obtusifoliol, leads to impairment of membrane function and inhibition of growth. 16 Individual agents differ in their effects on individual fungi because of major differences in the nature of the accumulating 14 -methylsterols. 16 In A. fumigatus the addition of itraconazole leads to the accumulation of eburicol which has deleterious effects on membrane function. It also results in the accumulation of the 3-ketosteroid, obtusifolione, which damages membrane structure. 16 Accumulation of 3-ketosteroid has been attributed to an interaction (direct or indirect) between itraconazole and the 3-ketosteroid reductase involved in the 4-demethylation step of fungal ergosterol biosynthesis.
Accumulation of obtusifolione could account for the lethal effect of this drug on A. fumigatus and some other species of fungi, but it remains to be seen whether the fungicidal effect of voriconazole is due to this or other mechanisms.
Our findings confirm and extend those of several recent reports which suggested that voriconazole has a fungicidal effect on A. fumigatus. 12, 13 In addition to A. flavus and A. fumigatus we investigated the in-vitro activities of this new agent against a range of pathogenic moulds, and compared the results with those obtained for itraconazole and amphotericin B. As shown in the Table, the two triazole agents were fungicidal for the two Aspergillus spp. as well as three dematiaceous moulds, C. bantiana, E. dermatitidis and F. pedrosoi. In addition, voriconazole was fungicidal for another dematiaceous mould, P. parasitica.
Our findings also confirm those of a recent investigation which found voriconazole to be less effective than itraconazole or amphotericin B against five isolates of the mucoraceous mould, R. arrhizus. 10 In the present investigation, the MIC range for voriconazole for ten isolates each of A. corymbifera and R. arrhizus was 4-16 mg/L, compared with 0.25-4 mg/L for itraconazole and 0.06-0.25 mg/L for amphotericin B.
Our results confirm recent reports that voriconazole is more active than amphotericin B or itraconazole against S. apiospermum. 6, 8, 10 However, none of the compounds tested in this investigation were fungicidal for this mould. The MICs of voriconazole for F. solani have been variable, with ranges of 1-4 mg/L and 8-16 mg/L described in two previous reports. 6, 8 The MIC range obtained in this investigation (1-4 mg/L) was identical to that found in our previous evaluation 8 and much lower than that obtained for itraconazole. Neither triazole showed significant fungicidal effects on F. solani, unlike amphotericin B. The MICs of voriconazole for S. schenckii have also been variable, with ranges of 0.5-16 mg/L, 0.5-4 mg/L and 8-16 mg/L described in earlier reports. 6, 8, 10 The MIC range obtained in this investigation (0.12-16 mg/L) was wider than that found in our earlier work 8 and similar to that obtained for itraconazole. Neither triazole showed fungicidal effects on S. schenckii, unlike amphotericin B.
Our results suggest that voriconazole, like itraconazole, is a broad-spectrum antifungal agent, effective against a wide range of moulds in vitro. It remains to be seen to what extent the low MICs and MLCs seen with voriconazole in this and other investigations will be predictive of clinical outcome. However, initial results from animal models and clinical trials suggest that voriconazole is effective in disseminated aspergillus infection. 2, 3, 7, 17, 18 Our findings suggest that further clinical evaluation of voriconazole in other mould infections is justified.
